Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Vaccine Regimen ALVAC-HIV (vCP1521) Followed by AIDSVAX® B/E in Healthy, HIV-1 Uninfected Adult Participants in South Africa

NCT02109354 is registered in ClinicalTrials.gov with HIV Vaccine Trials Network as lead sponsor.

NCT NCT02109354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02109354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Vaccine Regimen ALVAC-HIV (vCP1521) Followed by AIDSVAX® B/E in Healthy, HIV-1 Uninfected Adult Participants in South Africa
Lead sponsor
HIV Vaccine Trials Network
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2013
Completion date
February 2, 2015
Enrollment
202 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection